Principles for constructing a tuberculosis treatment regimen Institute of Tropical Medicine
Current World Health Organization guidelines for the formulation of treatment regimens for multidrug-resistant tuberculosis (MDR-TB) pay too little attention to the microbiological activity of anti-tuberculosis drugs. Here, we draw lessons from the pioneering work done on shorter MDR-TB treatment regimens and the current knowledge of the bactericidal and sterilizing properties of the drugs to inform the composition of treatment regimens for ...
Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Vrije Universiteit Brussel
new treatment option for in vitro fertilization (IVF) patients to initiate and sustain
the first 7 days of ovarian stimulation for IVF/intracytoplasmic sperm injection.
Peak follicle-stimulating hormone (FSH) activity is reached within 2 days
after corifollitropin alfa administration and then declines. Daily recombinant
FSH (rFSH) is ...
The international prevalence and variability of nonadherence to the nonpharmacologic treatment regimen after heart transplantation: Findings from the cross-sectional BRIGHT study KU Leuven
Aerosolization of nanotherapeutics as a newly emerging treatment regimen for peritoneal carcinomatosis Ghent University
Challenging the prescribed enrofloxacin treatment regimen of bacterial respiratory disease caused by Ornithobacterium rhinotracheale and Escherichia coli in turkeys Ghent University
Bilateral pedal edema in an HIV patient: lopinavir/ritonavir-containing treatment regimen as a potential cause? Institute of Tropical Medicine
Lessons learned from 2 patients with multidrug-resistant HIV-1 infection successfully treated with a darunavir-containing antiretroviral treatment regimen Institute of Tropical Medicine
Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB Institute of Tropical Medicine
Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries Institute of Tropical Medicine
SETTING: Nine countries in West and Central Africa.
OBJECTIVE : To assess outcomes and adverse drug events of a standardised 9-month treatment regimen for multidrug-resistant tuberculosis (MDR-TB) among patients never previously treated with second-line drugs.
DESIGN: Prospective observational study of MDR-TB patients treated with a standardised 9-month regimen including moxifloxacin, clofazimine, ethambutol (EMB) and pyrazinamide ...